JPRN-jRCT2080221918未知1 期
DS-7250 -Evaluation of Safety, Pharmacokinetics, and Pharmacodynamics After Multiple Oral Administration in Patients With Type 2 Diabetes
DAIICHISANKYO Co.,Ltd.0 个研究点开始时间: 2012年9月13日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •The patients who are diagonosed with type 2 diabetes mellitus
排除标准
- 未提供
研究者
相似试验
招募中
1 期
Evaluation of safety and pharmacokinetic parameters of the PTI5803 productEpilepsyCTIS2024-512472-35-00Panntherapi8
招募中
1 期
A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors-JPRN-jRCT2080225128-6
尚未招募
1 期
Safety and pharmacokinetics of CIGB-552Solid tumorsRPCEC00000196Center for Genetic Engineering and Biotechnology (CIGB)
招募中
1 期
Phase 1 study of 211At-MABG in patients with pheochromocytoma/pargangliomaPheochromocytoma, paragangliomaD010673, D010235JPRN-jRCT2021220012Shiga Tohru18
已完成
不适用
A study to evaluate the pharmacokinetics, safety and tolerability after inhalation of MMI-0100 in healthy subjects; MMI-0100 is an investigational drug developed for the treatment of fibrotic indications.Idiopathic pulmonary fibrosisidiopathische fibrosepulmonary diseases.NL-OMON40896Moerae Matrix, Inc48